Asthma is a chronic inflammatory disease of the airways affecting approximately 300 million individuals worldwide (Ref. 1) . The prevalence of asthma increased dramatically in many Western countries during the last 30 years of the 20th century and is now greater than 10% (Ref. 2) . In several Western countries, the rates of asthma have reached a plateau since the 1990s, especially in adults (Ref. 3 ). Nevertheless, the high incidence of asthma represents a huge economic burden. For example, the cost to the US economy attributable to asthma was estimated to be US$12.7 billion in 1998 (Ref. 4) . Furthermore, high levels of nonatopic asthma have been recognised in the developing world (Ref. 5 ).
Asthma involves recurrent episodes of airway obstruction and wheezing, ranging in severity from mild to life-threatening. The majority of asthmatics have a characteristic allergic inflammatory response in the lungs involving excessive activation of T helper 2 (Th2) cells, eosinophil infiltration, mucus overproduction, and airway hyper-reactivity. In many cases, this results from an allergic response to environmental allergens (Ref. 6) . It is important to note that asthma is highly heterogeneous, and that the asthmatic inflammatory response does not always correspond closely to classical allergy. For example, a significant number of asthmatics have an inflammatory pathology dominated largely by neutrophils rather than eosinophils (Ref. 7) . The heterogeneity of asthma is beyond the scope of this review, and we focus here principally on the cellular and molecular mechanisms underlying allergic airway inflammation (AAI).
Animal studies have been valuable for elucidating the cellular and molecular pathways required for AAI. Murine models have been particularly useful, because of the many tools available to dissect mechanisms of allergic inflammation.
Neutralising antibodies, transgenic mice (usually overexpressing selective genes) and knockout mice (lacking selective genes) are particularly powerful in assessing the role of individual molecules and cells (Ref. 8) . The popularity of such models needs to be considered against their limitations (Ref. 9 ). There are many structural and functional differences between mice and humans, and mice do not spontaneously develop asthma. Experimental AAI is usually induced artificially by parenteral administration of allergen in adjuvant. Furthermore, in a standard murine AAI model, degranulated eosinophils are detected only in the airway lumen and not in the lung tissue (Ref. 10) .
The vast majority of animal studies assess acute responses to inhalation of high concentrations of antigen, which generate vigorous cellular infiltration but are not good models of airway remodelling, a common feature of established asthma. A chronic model has been developed that has more histological similarities to clinical asthma (Ref. 11) . In another chronic model, mice were followed for several weeks after cessation of challenge. AAI resolved, but airway hyper-responsiveness (AHR) and remodelling did not resolve during the period of observation (Ref. 12 ). There are, however, relatively few studies on chronic allergen exposure. Furthermore, the standard mouse models do not reliably demonstrate the earlyand late-phase responses that are characteristic of clinical asthma (Ref. 13 ). Finally, results in mouse models may differ markedly between strains, making it difficult to extrapolate findings to clinical asthma. Despite these limitations, mouse models are widely used to identify potential targets and to assess new therapeutic agents (Refs 8, 14) . This review draws heavily on animal models of AAI. Clinical trials of novel therapeutic agents are also included, but we do not attempt a comprehensive coverage of descriptive clinical studies.
Differentiation of effector T helper cells

CD4
þ Th cells are necessary for the pathogenesis of AAI. Depletion of murine CD4
þ Tcells prevents antigen-induced pulmonary eosinophilia and AHR (Ref. 15 ). The Th2 subset, which controls the allergic response through the production of cytokines such as interleukin (IL)-4, IL-5, IL-9 and IL-13, is particularly prominent in allergic asthma (Refs 16, 17) . The key role of Th2 cells is illustrated in Figure 1 . Differentiation of naive CD4 þ T cells is a tightly regulated process. Experiments in mice have demonstrated that the cytokine microenvironment has a major role in regulating T cell differentiation, but other factors such as antigen concentration, and expression of costimulatory molecules and Notch ligands, also contribute (Refs 18, 19) .
IL-4 signalling through STAT6 (signal transducer and activator of transcription 6) was originally thought to be necessary for Th2 cell commitment (Refs 20, 21 While the Th1 -Th2 paradigm is over two decades old, a third, distinct Th cell subset has recently been recognised. The Th17 subset is defined on the basis of secretion of the cytokine IL-17, now known as IL-17A, which has been particularly associated with neutrophilic inflammation. Th17 cells also produce IL-17F, which has a number of similar effects to IL-17A (Ref. A role for Treg has been demonstrated in studies on mouse models of AAI. In one approach, antigen-specific CD4 þ CD25 þ Treg cells were transferred into antigen-sensitised animals prior to challenge. The Treg reduced the resulting AHR, lung eosinophil infiltration, and Th2 cytokine production (Ref. 48). These effects depended on IL-10 production in the recipient, but did not require IL-10 production by the Treg themselves. In an alternative approach, depletion of Treg with an anti-CD25 antibody prior to antigen sensitisation increased AHR, eosinophil infiltration and Th2 cytokine production, and elevated the capacity of pulmonary dendritic cells to elicit a Th2 response (Ref. 49). In another study, when mice were treated with cyclophosphamide prior to sensitisation, the resulting pulmonary eosinophil infiltration and Th2 response were greatly increased, and this was associated with a reduction of FOXP3 expression in the lungs and lymphoid organs, suggesting that cyclophosphamide depletes Treg (Ref. 50 ). In a model of tolerance induced by respiratory exposure to allergen, pulmonary dendritic cell production of IL-10, and the resulting production of IL-10 by Treg, was required for the induction of mucosal tolerance (Ref. 51) . In a rat model of chronic aeroallergen exposure, Treg appeared in the respiratory mucosa and regional lymph nodes within 24 h of initial antigen exposure, and prevented further AHR (Ref. 52) . Taken together, these animal studies indicate that Treg inhibit the extent of allergic inflammation.
Regulatory T cells
There is emerging evidence that Treg can control Th2 responses in humans.
cells, whereas inhibition by CD4
þ CD25 þ T cells from atopic donors was much less effective (Ref. 53) . In a study on cytokine production by individual blood T cells, the dominant allergen-specific cells were IL-10-secreting in healthy individuals, resembling a type of inducible Treg known as T regulatory 1 (Tr1) cells. By contrast, in atopic individuals, the most abundant allergen-specific cells were Th2-like IL-4 secretors (Ref. 54) . Both these papers propose that atopy may be associated with an imbalance between Th2 cells and Treg.
The effects of Treg could account for some of the observations associated with the 'hygiene hypothesis'. This hypothesis attempts to explain the recent increased incidence of asthma in developed countries on the basis of reduced exposure to infectious agents, especially during early life. Early studies suggested that skewing of the Th response towards Th2 and away from Th1, because of reduced exposure to Th1-inducing pathogens, was a major contributor to increased asthma incidence. However, several observations argue against this. First, there is increasing evidence that in asthma in humans, and AAI in animals, Th1 cytokines contribute to pathogenesis (see section 'Th1 cytokines' below). Second, the incidence of several Th1-cytokine-driven inflammatory diseases such as type 1 diabetes also increased in the late 20th The role of dendritic cell expression of Notch ligands in Th1 and Th2 differentiation is reviewed above in 'Differentiation of effector T cells'.
Eosinophils
Airway eosinophilia is a key feature of AAI. Eosinophils produce leukotriene (LT) C4, major basic protein and a broad range of cytokines and proallergic mediators (Ref. 70). However, there are conflicting results on the association between eosinophils and AHR. In some studies, using IL-5-knockout mice or neutralising anti-IL-5 antibody, in which eosinophils were depleted, AHR was abolished (Refs 71, 72). However, other reports failed to demonstrate an association between eosinophilia and AHR. In a study on mice treated with anti-IL-5 antibody, eosinophils were depleted but AHR was not affected (Ref. 73) , and other mouse models of AAI have been reported in which eosinophils were not required for AHR (Refs 74, 75) .
Findings in recently developed eosinophildeficient mice have also been controversial. In one strategy for generating eosinophil-deficient mice, knockout of a high-affinity GATA site in the GATA-1 promoter effectively deleted eosinophils but not other leukocyte lineages. Assessment of these 'Ddbl GATA' mice in AAI revealed that loss of eosinophils did not affect mucus hypersecretion or AHR, although subepithelial collagen deposition was reduced after prolonged allergen challenge (Ref.
One explanation for the discrepant results could lie in the differing genetic backgrounds of the two strains. The Ddbl GATA mice were bred on the Th2-susceptible BALB/c background while the PHIL mice originated from the Th2-resistant C57BL/6 background. These discrepant results highlight limitations in the capacity of mouse models to predict mechanisms in human asthma. The role of eosinophils in AAI remains controversial. Furthermore, human studies have failed to demonstrate a causal relationship between eosinophil infiltration and asthma (see section 'IL-5' below).
Mast cells
Along with eosinophils, another enigmatic cell type in asthma is the mast cell. These cells are packed with a host of preformed inflammatory molecules including histamine, TNF-a, and tryptases and chymases, which are serine proteases. Granule contents are released in response to numerous stimuli, of which the most relevant to AAI is crosslinking of the high-affinity IgE receptor (Fc1R1), and also perhaps Toll-like receptor signalling (Ref. 78 ). In addition to preformed mediators, mast cells also secrete de novo synthesised cytokines, chemokines and inflammatory lipids after activation (Ref. 79, 80 There are few reports that specifically address the mechanisms of airway epithelial cell function in vivo in AAI. These studies have utilised the Clara cell 10 kDa secretory protein 
IL-5
The prominent airway and lung tissue eosinophilia in allergic asthma has led to a focus on the mediators that govern the production, survival and activation of eosinophils. IL-5 fulfils all these functions and is elevated in bronchoalveolar lavage fluid from human asthmatics and allergic mice (Refs 70, 114). IL-5 acts on bone marrow progenitors to accelerate the production of eosinophils (Ref. 
IL-13
IL-13 binds to the IL-4Ra -IL-13Ra1 receptor complex, as does IL-4, and shares many effects with IL-4 (Refs 126, 127). As mentioned above, IL-4 also signals through the receptor formed by the IL-4Ra chain and gc, and there is an additional IL-13 receptor chain, the IL-13Ra2 chain, which can act as a decoy receptor, inhibiting the effects of IL-13 (Ref. 128 ).
Administration of recombinant IL-13 to the airways of naive mice strongly induces mucus secretion in airway epithelial cells and is sufficient to induce both airway eosinophilia and IgE production. Neutralisation of IL-13 with a soluble fusion protein prevents AHR in an AAI model in mice (Refs 127, 129) . The crucial action of IL-13 acting directly at the level of the airway epithelium was demonstrated by a compelling study (Ref. 101) , where overexpression of IL-13 restricted to the airway epithelium was sufficient to induce AHR and mucus production. The IL13Ra2 chain has an important role in regulating AAI. In a model of AAI, mice lacking this receptor chain exhibited enhanced AHR, mucus production and fibrosis (Ref. 130) .
The discovery that IL-4 and IL-13 share receptors has led to the development of a receptor antagonist molecule, pitrakinra, that inhibits both cytokines. It is an IL-4 variant that competitively inhibits receptor complexes containing the IL-4Ra chain, thereby interfering with the actions of both IL-4 and IL-13. In a recent report on patients with allergic asthma, administration of pitrakinra, either subcutaneously or by inhalation, reduced the late-phase response to allergen (Ref. 131) . This report provides good evidence for a role for Th2 cytokines in clinical allergic asthma, and suggests that simultaneous inhibition of more than one Th2 cytokine may be necessary for beneficial effects.
Th1 cytokines
Type 1 cytokines such as IFN-g and IL-12 inhibit Th2-cell differentiation and Th2 cytokine effector function. For this reason, Th1 cytokines were originally regarded as potentially protective against asthma, which was considered a purely Th2 response (Ref. 18) . Interestingly, an attempt to inhibit the Th2 response in asthmatics through recombinant IL-12 therapy reduced airway eosinophil numbers but not AHR (Ref. 132) , which indicates a more complicated role for Th1 cytokines in asthma than is suggested by the earlier Th1 -Th2 imbalance paradigm. In fact, a number of studies have reported enhanced IFN-g levels in asthmatic patients, suggesting that IFN-g and Th1 cells may in fact be pathogenic in asthma (Refs 133, 134) .
In mouse asthma models, while some studies showed protective effects of Th1 cells (Refs 36, . 138, 139 ). These studies, taken together with the clinical studies described in the previous paragraph, suggest that Th1 cells and IFN-g contribute to the pathogenesis of AAI and asthma.
IL-17A
In clinical asthma, IL-17A is overexpressed in the airways and is associated with neutrophil influx (Ref. 
Additional cytokines regulating AAI
Other cytokines have been shown to be involved in murine models and may have a role in clinical asthma. These include IL-25, which is also known as IL-17E because it is structurally a member of the IL-17 family. IL-25 is produced by Th2 cells and promotes airway inflammation and AHR in mice in an IL-13-dependent fashion (Ref. 167 ). The cytokine amphiregulin, a member of the epidermal growth factor family, is produced by activated mast cells and is associated with mucus production in asthmatic airways (Ref. It is important to note that AAI is a highly complex process, and that the activity of a vast array of cytokines and chemokines in addition to those described above is required for pathogenesis. Nevertheless, clinical experience with inhibition of TNF in rheumatoid arthritis (Ref. 145 expert reviews http://www.expertreviews.org/ in molecular medicine
